8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Apr 1, 2026·SEC
Alto Neuroscience, Inc.(ANRO)Earnings, Financials & Key Ratios
ANRO•NYSE
$25.70
Price updated Jul 7, 2026
AboutAlto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.Show more
- Revenue$0
- EBITDA-$66M+11.7%
- Net Income-$63M-2.9%
- EPS (Diluted)-2.19+12.4%
- ROE-41.8%+72.9%
ANRO Price & Volume
Alto Neuroscience, Inc. (ANRO) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Scaling Drives Persistent Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Binary clinical trial outcomes
Key Thesis Takeaways
- Alto Neuroscience remains in a high-risk, pre-revenue development phase, relying on its proprietary neurophysiological biomarker platform to differentiate its psychiatric drug candidates.
- While the company has successfully bolstered its balance sheet to support ongoing clinical trials, the lack of commercial revenue and widening operating losses present significant long-term execution risks.
- Investors should monitor the upcoming binary clinical data readouts, such as ALTO-100, as the primary catalyst for valuation, given the current absence of operational leverage.
Verdict Logic
while the company maintains a robust liquidity profile with $263.8 million in cash as of 2026Q1, the lack of commercial revenue and reliance on binary clinical trial outcomes warrant a cautious, wait-and-see approach.
ANRO Growth Metrics
Alto Neuroscience, Inc. (ANRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.44%
Return on Capital
10 Years-55.89%
5 Years-55.89%
3 Years-51.34%
Last Year-38.93%
ANRO Recent Earnings
Alto Neuroscience, Inc. (ANRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (60%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.80-42.9%
$0.56
Rev
—
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.45+19.6%
$0.56
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.52+21.2%
$0.66
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.65-14.0%
$0.57
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.80vs $0.56-42.9% | — |
| Q2 2026 | Mar 16, 2026 | $0.45vs $0.56+19.6% | — |
| Q4 2025 | Nov 12, 2025 | $0.52vs $0.66+21.2% | — |
| Q3 2025 | Aug 13, 2025 | $0.65vs $0.57-14.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Alto Neuroscience, Inc. (ANRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.70 | $901.91M | -11.74 | — | — | -41.8% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $249.76 | $12.85B | -67.87 | 65.55% | -26.59% | -260.01% | — |
Compare ANRO vs Peers
Alto Neuroscience, Inc. (ANRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANRO SEC Filings & Documents
Alto Neuroscience, Inc. (ANRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANRO Frequently Asked Questions
Alto Neuroscience, Inc. (ANRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ANRO profitable?
Alto Neuroscience, Inc. (ANRO) reported a net loss of $74.3M for fiscal year 2025.
Dividend & Returns
What is ANRO's return on equity?
Alto Neuroscience, Inc. (ANRO) has a return on equity (ROE) of -41.8%. Negative ROE indicates the company is unprofitable.
What is Alto Neuroscience, Inc.'s free cash flow?
Alto Neuroscience, Inc. (ANRO) had negative free cash flow of $62.9M in fiscal year 2025, likely due to heavy capital investments.